After failed listing attempts in the US and UK, China's Shein to file confidentially for Hong Kong IPO: What makes this a rare move for Chinese company
Shein, the China-founded fast-fashion giant, is reportedly set to file a draft prospectus confidentially for an
initial public offering
(IPO) in Hong Kong, potentially as early as this week, according to a report in Reuters that quotes three sources familiar with the matter. The move, as per Reuters exclusive report, could make Shein one of the largest IPOs in Hong Kong this year. The IPO also reportedly marks a rare departure from the city's norm of public IPO filings and follows Shein's failed listing attempts in the U.S. and London.
What is confidential IPO filing
The confidential filing, expected by Monday (June 30), would allow Shein to shield sensitive financial and operational details during the regulatory review process, a practice more common in the U.S. than in Hong Kong. This approach requires a waiver from the Hong Kong stock exchange's standard listing rules, which typically mandate public disclosure of IPO documents. The exchange may grant such exemptions for secondary listings or spinoffs from companies listed on recognized overseas exchanges like the NYSE or Nasdaq. Shein, however, is pursuing a primary listing, making the confidential approach unusual for the city, where high-profile IPOs like Xiaomi and Meituan involved public filings.
Shein, valued at $66 billion in its 2023 pre-IPO fundraising round, must secure approval from the China Securities Regulatory Commission (CSRC) before proceeding with the
Hong Kong IPO
. The company will need to file with the CSRC within three days of submitting its Hong Kong application, in line with Chinese regulations for offshore listings. It remains unclear whether Shein has received preliminary approval from the CSRC. The Hong Kong stock exchange and Shein declined to comment, and the CSRC did not respond to inquiries.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
USDJPY đang đi lên không?
IC Markets
Đăng ký
Undo
How Shein has been impacted by the US-China trade war
The filing comes as Shein navigates challenges from the U.S.-China trade war, with new U.S. tariffs on Chinese goods and the end of duty-free treatment for e-commerce parcels impacting its largest market. Shein, which sells low-cost apparel like $5 dresses and $10 jeans in 150 countries, shifted its headquarters to Singapore in 2022 but relies on a network of 7,000 Chinese suppliers, subjecting it to Beijing's IPO oversight. The company has also faced allegations of forced labor in its supply chain, which it denies, stating it prohibits suppliers from using Chinese cotton in U.S.-bound products.
When Shein's attempt to list in the New York exchange failed
Shein's pivot to Hong Kong follows an unsuccessful bid to list in the U.S. in late 2023. The company filed for a New York IPO but failed to secure CSRC approval, Reuters previously reported. The attempt was further complicated by U.S. regulatory scrutiny and trade tensions, including accusations from lawmakers and activists that Shein's supply chain involves forced labor in Xinjiang, a claim the company has rejected. The U.S. ban on imports linked to forced labor added pressure, and Shein's valuation dropped by a third from 2022 to 2023 amid these challenges. After the U.S. listing stalled, Shein explored a London IPO but was unable to gain Chinese regulatory approval, prompting the shift to Hong Kong as a more viable listing venue.
A successful Hong Kong IPO could bolster the city's status as a global fundraising hub, which saw $12.8 billion in IPOs and secondary listings in the first half of 2025. Shein's listing, however, hinges on navigating regulatory hurdles and addressing concerns about its supply chain and the impact of U.S. tariffs, which could influence its final valuation.
AI Masterclass for Students. Upskill Young Ones Today!– Join Now
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hindustan Times
40 minutes ago
- Hindustan Times
Elon Musk slams Donald Trump's tax bill for slashing electric vehicle credits: ‘Incredibly destructive'
Jun 30, 2025 06:38 AM IST Elon Musk slammed the US Senate's latest version of President Donald Trump's multi-trillion dollar tax bill Saturday, warning that the cuts to electric vehicle and other clean energy credits would be 'incredibly destructive' to the country. Musk recently left Trump's side after working for several months as the head of Trump's so-called Department of Government Efficiency.(REUTERS) Musk, the chief executive officer of Tesla Inc. and SpaceX, posted on his social media platform X about the bill, which the Senate advanced in a contentious vote late Saturday. Musk recently left Trump's side after working for several months as the head of Trump's so-called Department of Government Efficiency. The bill would destroy millions of US jobs and give 'handouts to industries of the past while severely damaging industries of the future,' Musk said. The tech billionaire's latest criticism of the package threatens to reawaken his public rift with Trump that began after the world's richest man left his cost-cutting job in the administration. Trump was asked about Musk in an interview that was recorded on Friday before the billionaire's most recent posts. 'I haven't spoken to him much, but I think Elon is a wonderful guy, and I know he's going to do well always,' Trump said on Fox News's Sunday Morning Futures with Maria Bartiromo, which aired Sunday. 'But he got a little bit upset, and you know that wasn't appropriate.' The Senate tax bill would bring a quicker end to a popular $7,500 consumer tax credit for electric vehicles. While the earlier proposal would have ended the incentive at the end of this year for most EV sales, the new version terminates the credit after Sept. 30. Tax credits for the purchase of used and commercial electric vehicles would end at the same time.
Time of India
an hour ago
- Time of India
Analysts betting on these four pharma, hospital stocks due to Indian healthcare sector's strong growth prospects
Pharma segment outlook Hospital segment outlook Sun Pharmaceuticals Gained market share in the domestic formulations segment in Q4 FY25, with 14% year-on-year revenue growth driven by higher volumes and new product launches. Missed Reuters-Refinitiv estimates, with revenue falling short by 3.3% and net profit by 13.3%, primarily due to weaker sales in the US and Rest of the World (RoW) markets. Domestic growth outlook supported by upcoming launches in anti-diabetes and weight management therapies; US growth to come from existing product sales. Plans to invest $100 million in specialty portfolio (dermatology and oncology) for product launches, promotions, and field force expansion. Motilal Oswal remains bullish, citing Sun's push for differentiated offerings in regulated markets to drive future earnings. Reported in-line revenue growth in Q4 FY25, while net profit beat Reuters-Refinitiv estimates by 19.1%, aided by higher other income and lower finance costs. India business drove revenue growth and is expected to remain strong, supported by its innovative portfolio and therapies like respiratory and urology. Recent US approvals for cancer drugs (Abraxane, Nilotinib) and upcoming respiratory launches over the next 12–18 months are expected to stabilise US performance. Management is focused on boosting manufacturing capacity, investing in R&D for differentiated products, and exploring inorganic growth opportunities. According to Antique Stock Broking, Cipla is entering a structural growth phase in the US generics market, driven by continued investment in complex generics, respiratory, and peptide segments. Apollo Hospitals Enterprise An integrated healthcare services provider, the company reported in-line revenue and a 5% net profit beat versus Reuters-Refinitiv estimates in Q4 FY25, supported by higher other income and a lower tax rate; the hospital segment delivered a mixed performance.. ARPOB rose 5% y-o-y driven by higher patient realisation; expected to improve further with better payer mix and rising surgical volumes. Plans to add 3,577 beds over 3-4 years; margin impact from new additions to be offset by cost optimisation. Pharmacy business outlook supported by growing GMV, new store openings, and efficiency measures. Diagnostics segment expected to revive, led by growth in primary and secondary clinics. Motilal Oswal sees positives in bed additions, better productivity at existing facilities, reduced pharmacy losses, and a likely turnaround in diagnostics profitability. Fortis Healthcare Posted in-line revenue and an 11.3% net profit beat in Q4 FY25, driven by higher ARPOB and better occupancy. Hospital revenue grew 14% y-o-y; diagnostics rose 3%. Management expects 14-15% hospital growth in 2025-26 and 24-25% diagnostics margins over 2–3 years. Expansion underway via greenfield projects and acquisitions (Manesar, Jalandhar). Elara Capital raised 2026-27 earnings estimates on strong growth guidance. The healthcare sector—including pharmaceuticals and hospitals— delivered a strong performance in the March 2025 quarter. The pharmaceutical segment benefited from increased demand in chronic therapies within the domestic formulations market, along with steady growth in the US generics business. Meanwhile, the hospitals segment was bolstered by expanded bed capacity and robust growth in average revenue per occupied bed (ARPOB).According to Reuters-Refinitiv data, 129 pharmaceutical companies—including those in biotechnology and life sciences— reported an aggregate revenue growth of 11.5% year-on-year (y-o-y) in the March 2025 quarter. Meanwhile, 26 healthcare providers, including diagnostic firms , recorded a 15.1% year-on-year revenue analysis includes only companies with a market capitalisation above `100 crore. In comparison, Nifty 500 companies posted a lower aggregate revenue growth of 6% healthcare sector performed well in 2024 amid global economic uncertainty driven by geopolitical tensions, trade disruptions, and interest rate volatility. The Nifty Healthcare Index emerged as the second-best performer among the 16 sectoral indices on the National Stock Exchange (NSE) over the past the sector's performance—particularly pharmaceuticals—has moderated in recent months due to concerns over the loss of exclusivity for generic Revlimid (gRevlimid), a cancer drug, which is expected to intensify competition and pressure prices and margins. Additionally, nearterm growth challenges in the domestic formulations segment have weighed on the sector the recent announcement by US President Donald Trump regarding potential tariffs on pharmaceutical imports has dampened investor sentiment. Indian pharmaceutical companies, which earn a significant share of their revenue from US exports, are expected to feel the impact. As a result, the Nifty Pharma Index has become the fourth worst-performing sectoral index on the NSE in 2025 so far, based on data as of 23 June long-term prospects of the pharmaceuticals sector remain intact. A recent Axis Securities report lists strong product pipeline in biosimilars, GLP-1 (class of drugs used to treat diabetes), and peptides (chain of amino acids used to treat diseases), stable margins, and higher contribution from chronic therapies as key growth catalysts for Indian pharmaceutical companies. Moreover, stability in price erosion, differentiated portfolio, and exposure to complex generics is expected to support the US generics concerns remain over the loss of exclusivity for gRevlimid, Indian pharmaceutical companies stand to gain from strong opportunities in the US generics market. The expiry of exclusivity is expected to accelerate generic launches, benefiting manufacturers— particularly Indian to a recent report by Antique Stock Broking, a combination of greater loss-of-exclusivity opportunities, rationalised global competition, and improved regulatory compliance is expected to drive revenue growth for Indian pharmaceutical companies through new product launches and volume gains in existing also see potential in the CDMO (contract development and manufacturing organisation) space. A BNP Paribas report highlights investor feedback suggesting that India stands to benefit as global innovators diversify supply chains away from China. However, concerns persist over high valuations in the segment and limited near-term earnings the hospital segment, factors such as the rise in lifestyle diseases, improving affordability and accessibility driven by higher disposable incomes, a significant demand-supply gap, growing medical tourism, a shift in payer mix due to increased insurance penetration, and bed capacity expansion by private players are expected to drive low healthcare spending in India compared to the world average, rising median age, and a pickup in highgrowth therapies such as cardiac and cancer care—which boost ARPOB and occupancy— are the additional growth catalysts. An IBEF report estimates the Indian hospital market to grow by 8% CAGR between 2022-23 and 2031-32 to reach $193.6 billion. Here are the four stocks (two each from the pharmaceuticals and hospitals segments) with strong analyst TAM growth (%)
Time of India
an hour ago
- Time of India
Indian family offices now go beyond investing for HNIs and are involved in legacy planning, capital preservation for the future: Umang Papneja, CEO, Julius Baer India
RAPID FIRE the one financial habit every young investor should adopt early?The art and science of saving! your biggest investing superstition that you know is totally irrational?That the markets generally fall in do you unwind after a volatile market day?Markets don't move in a straight line, they are inherently volatile. It really doesn't bother one investing myth you wish more people would stop believing? Real estate investment in India is better than stranded with only three stocks for 10 years, which ones you'll choose?I am bullish on the BFSI sector in India as I understand that better than other businesses so all my stock picks will be from this global market or economy fascinates you the most right now, and why?I believe in the India growth more dangerous to your returns – a business TV news channel or Twitter?WhatsApp University is the most dangerous!Wealth creation and preservation is not just an aspiration for the common man and woman. The rich and the famous also want to see their money grow. But more importantly, they'd like their wealth and legacy being passed on to future generations. A report by wealth management firm Julius Baer, in association with EY, estimates that US$ 1.5 trillion is expected to change hands in India over the next decade. A large chunk of this wealth sits in family offices —the 'money box' of affluent families—run with a strict constitution designed to grow the capital and pass it to future generations, alongside any mandates for charity or other causes. The Julius Baer-EY report titled 'The Indian family office playbook–June 2025' gives us an insight into the world of family offices, trends in their investment preferences, their risktaking abilities, succession planning and so on. Excerpts from the conversation with Umang Papneja, CEO, Julius Baer India:The amount of wealth creation in India is unparalleled. India is at number three, just behind US and China in terms of new people being added to the ultra high-networth individual (UHNI) list. A report says that around three individuals get added in the $30 million plus bracket every day in are the kinds of additions we're seeing to the elite club. Wealth managers and multi-family offices are targeting 1,000 new clients annually, and over the next five years, another 5,000 individuals are expected to join—each with an investable surplus of $30 million (Rs.250 crore). No wonder we have seen the number of family offices swell from 45 to people don't only want to manage and grow the money in terms of asset allocation and product selection. International investing and philanthropy too are on their aspiration list. The focus is also on how to preserve and sustain this level of wealth for future generations—two or even three down the line. That's the mindset change. I won't be surprised if there's an exponential increase in the number of family offices over the next four- five a new-generation entrepreneur has launched an IPO and sold part of their stake through an offer for sale, or brought in a private equity investor. With this liquidity, the entrepreneur can now consider setting up a family age has got nothing to do with this. The perception that senior people do not like risk and only youngsters do, is a misconception. That's because the patriarch, even if he is 75 years old, knows that he is not just saving the money for himself. The wealth is for the next generations as well. Why should he be conservative in his choice of investments and wealth creation? He obviously thinks about growing and compounding as well, so that his future generations are taken care of. Family offices work way beyond goals like retirement planning. They think about preserving and compounding wealth for future generations; it's a growth mindset at play offices invest in traditional products like listed equities, fixed income products, and so on. But new generation entrepreneurs also want to give back to the community where they come instance, if a startup founder had a successful exit and there was an ecosystem which supported him, he would want to give something back to the system. For instance, say 4-5% of his wealth may go towards a startup founded by peers in his cohort. We see a lot of that in the technology sector landscape. The new age family offices might give something away to startups, but that's not the case always, with legacy depends from family to family. Typically, and irrespective of how many goals a family office would have, its investment agenda has three sides to it. First is safety. Second, growth investments. And, third, aspiration or the risk-taking each family might allocate different proportions to this. Some might not want any safety element in the way they manage their money. A family office might say it needs to earmark a certain amount or a certain percentage of the overall corpus, in the safety basket, which will only invest in risk-free or least risky instruments, and so on. But all of this is laid out in the family office's constitution at a broader level and more specifically, in their investment policy course, they still invest in mutual funds. That's the bread and butter. But they also aspire to grow their wealth. And the buckets that I just explained, also has a risk bucket in the midst. Most family offices restrict investments in alternate assets to around 10% of their overall corpus. There are growing opportunities in the private equity space—especially as government spending rises in sectors like manufacturing and defence. Many new companies are emerging in these areas, but they are still in the early growth stages and not yet listed. Savvy and smart investors like family offices might not want to wait till they get listed to make money out of them. For example, as iPhones get locally-made, they might turn to small local companies to supply parts. Some of these companies can provide tremendous growth opportunities, especially since they get access to them at early only thing to remember here is that liquidity in unlisted companies and private equity is very low. Hence, most family offices prefer to restrict their investments in alternate assets to under 10%.Patriarchs and matriarchs would certainly like to decide how the next generation takes over. Without a plan, it can become emotional or even create friction. It gets even more complex in larger families. Nearly 60% of family offices take succession planning head on. It's important. In our experience, families that plan early, tend to transition more smoothly.A trust is perpetual. If assets are transferred to a trust, the trustees will transfer assets to the next generation exactly as per the wishes of the person who has made the trust. It becomes automatic and more longterm. A trust deed ensures that assets can be distributed for long enough, to as many beneficiaries as the trust deed mentions and over a long time. It gives you enough number of permutation and combinations and works well for families with complex assets or if the members are spread across geographies. A will, on the other hand, needs to be executed immediately upon the person's this is something we are seeing more often. Younger family members may want to follow different careers or investment paths. In such cases, having a family office structure helps, because it gives them a way to manage their share of wealth and income separately, but still with some family oversight. It also allows families to stay connected through shared values, while giving freedom for individual choices. It's not always easy, but the right governance structure and family oversight offices are increasingly investing in real assets because they offer stable, long-term income. These are not linked to market ups and downs in the same way as equities. REITs and InvITs, for example, give them exposure to assets like commercial buildings, roads, warehousing or data centres, these spaces are leased under long-term contracts, creating stable monthly income for investors. This investment class brings in regular cash flows, which suits families looking for steady returns without taking on too much remains a strong long-term story. Even with the current global tensions, we've seen that domestic liquidity is high, and that has helped markets stay steady. A few years ago, we may have seen sharper corrections, but that's not the case today. We continue to be positive on India's fundamentals. Sectors like banking, infrastructure, renewables and manufacturing are all seeing good momentum. So while it's important to stay balanced, this is also the time to look for the right opportunities with a long-term lens.
